Shanghai Pharmaceuticals Holding Co., Ltd logo

Shanghai Pharmaceuticals Holding Co., Ltd

2607.HK

HKSEHealthcareMedical - Distribution

Latest quote

HK$11.52

−HK$0.15 · -1.29%

Aug 24, 3:27 PM HKT

2607.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Qiuhua Yang
Listed since
May 20, 2011
Employees
49,608

Market position

Day range

Current HK$11.52

52-week range

Current HK$11.52

Open
HK$11.71
Previous close
HK$11.67
Volume
1.38M
0.52× average
Average volume
2.66M
Average daily volume
Market cap
66.82B HKD
Beta
0.22
Market reference 1
50-day average
HK$11.8486
-2.77% below average
200-day average
HK$11.7929
-2.31% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
54.66B CNY
P/E (TTM)
10.31×
P/B (TTM)
0.78×
P/S (TTM)
0.21×
EV / EBITDA
3.8×
Earnings yield
15.10%
Free cash flow yield
10.10%
Dividend yield
2.90%

Profitability & efficiency

Gross margin
10.83%
Operating margin
3.53%
Net margin
2.02%
Return on equity
7.54%
Return on assets
2.46%
Return on invested capital
4.97%

Financial health

Debt / equity
0.81×
Current ratio
1.33×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends14%10%5%0%Gross margin, FY2021: 13.23%Gross margin, FY2022: 13.14%Gross margin, FY2023: 11.88%Gross margin, FY2024: 11.13%Gross margin, FY2025: 10.73%Operating margin, FY2021: 3.80%Operating margin, FY2022: 3.89%Operating margin, FY2023: 2.95%Operating margin, FY2024: 2.96%Operating margin, FY2025: 3.51%Net margin, FY2021: 2.36%Net margin, FY2022: 2.42%Net margin, FY2023: 1.45%Net margin, FY2024: 1.65%Net margin, FY2025: 2.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 13.23%. Gross margin FY2022 13.14%. Gross margin FY2023 11.88%. Gross margin FY2024 11.13%. Gross margin FY2025 10.73%. Operating margin FY2021 3.80%. Operating margin FY2022 3.89%. Operating margin FY2023 2.95%. Operating margin FY2024 2.96%. Operating margin FY2025 3.51%. Net margin FY2021 2.36%. Net margin FY2022 2.42%. Net margin FY2023 1.45%. Net margin FY2024 1.65%. Net margin FY2025 2.02%.

Income trends

Revenue

283.58B CNY+3.03%

Operating income

9.94B CNY+22.13%

Net income

5.72B CNY+25.74%
Income trends across reported periods311.56B CNY199.64B CNY87.71B CNY−24.21B CNYRevenue, FY2021: 215.82B CNYRevenue, FY2022: 231.98B CNYRevenue, FY2023: 260.3B CNYRevenue, FY2024: 275.25B CNYRevenue, FY2025: 283.58B CNYOperating income, FY2021: 8.21B CNYOperating income, FY2022: 9.01B CNYOperating income, FY2023: 7.67B CNYOperating income, FY2024: 8.14B CNYOperating income, FY2025: 9.94B CNYNet income, FY2021: 5.09B CNYNet income, FY2022: 5.62B CNYNet income, FY2023: 3.77B CNYNet income, FY2024: 4.55B CNYNet income, FY2025: 5.72B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 215.82B CNY. Revenue FY2022 231.98B CNY. Revenue FY2023 260.3B CNY. Revenue FY2024 275.25B CNY. Revenue FY2025 283.58B CNY. Operating income FY2021 8.21B CNY. Operating income FY2022 9.01B CNY. Operating income FY2023 7.67B CNY. Operating income FY2024 8.14B CNY. Operating income FY2025 9.94B CNY. Net income FY2021 5.09B CNY. Net income FY2022 5.62B CNY. Net income FY2023 3.77B CNY. Net income FY2024 4.55B CNY. Net income FY2025 5.72B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue283.58B CNY275.25B CNY260.3B CNY231.98B CNY215.82B CNY
Cost of goods sold253.16B CNY244.62B CNY229.37B CNY201.49B CNY187.28B CNY
Gross profit30.42B CNY30.63B CNY30.93B CNY30.49B CNY28.54B CNY
Research and development2.34B CNY2.39B CNY2.2B CNY2.11B CNY1.99B CNY
Selling, general, and administrative18.52B CNY9.53B CNY10.9B CNY15.48B CNY14.73B CNY
Operating expenses20.47B CNY22.49B CNY23.26B CNY21.71B CNY20.62B CNY
Interest income404.97M CNY522.39M CNY387.82M CNY438.3M CNY338.18M CNY
Interest expense1.69B CNY1.63B CNY1.66B CNY1.69B CNY1.52B CNY
Depreciation and amortization2.86B CNY2.42B CNY2.19B CNY2.22B CNY2.14B CNY
Operating income9.94B CNY8.14B CNY7.67B CNY9.01B CNY8.21B CNY
Net income5.72B CNY4.55B CNY3.77B CNY5.62B CNY5.09B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-19.99%
11 comparable reports
Latest EPS result
0.43
Estimate 0.4 · Beat by 7.63%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.990.70.410.13Q4 '24BeatQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 0.3, estimate 0.27, surprise +11.11%, Beat. Q1 2025, reported Mar 26, 2025: actual 0.15, estimate 0.25, surprise -40.04%, Miss. Q2 2025, reported Apr 24, 2025: actual 0.384, estimate 0.448, surprise -14.30%, Miss. Q3 2025, reported Aug 28, 2025: actual 0.924, estimate 0.91, surprise +1.54%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.208, estimate 0.306, surprise -32.15%, Miss. Q1 2026, reported Mar 26, 2026: actual 0.178, estimate 0.217, surprise -17.93%, Miss. Q2 2026, reported Apr 29, 2026: actual 0.432, estimate 0.401, surprise +7.63%, Beat. Q3 2026, reported Aug 27, 2026: actual —, estimate 0.762, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates91.13B82.85B74.58B66.3BQ4 '24BeatQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 77.7B HKD, estimate 71.43B HKD, surprise +8.78%, Beat. Q1 2025, reported Mar 26, 2025: actual 69.81B HKD, estimate 76.42B HKD, surprise -8.65%, Miss. Q2 2025, reported Apr 24, 2025: actual 75.51B HKD, estimate 73.91B HKD, surprise +2.16%, Beat. Q3 2025, reported Aug 28, 2025: actual 77.5B HKD, estimate 73.93B HKD, surprise +4.82%, Beat. Q4 2025, reported Oct 30, 2025: actual 80.33B HKD, estimate 79.25B HKD, surprise +1.37%, Beat. Q1 2026, reported Mar 26, 2026: actual 76.24B HKD, estimate 73.35B HKD, surprise +3.94%, Beat. Q2 2026, reported Apr 29, 2026: actual 85.53B HKD, estimate 75.99B HKD, surprise +12.56%, Beat. Q3 2026, reported Aug 27, 2026: actual —, estimate 87.62B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.4491

2025 complete year-22.1% since 2021

2026 partial: HK$0.4048

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 15, 2026

HK$0.4048

Semi-Annual

Record Jul 16, 2026 · Payment Aug 24, 2026

Dividend

Ex-dividend Dec 29, 2025

HK$0.1322

Semi-Annual

Record Dec 31, 2025 · Payment Feb 6, 2026

Dividend

Ex-dividend Jul 16, 2025

HK$0.317

Annual

Record Jul 17, 2025 · Payment Aug 25, 2025

Dividend

Ex-dividend Sep 17, 2024

HK$0.0874

Semi-Annual

Record Sep 19, 2024 · Payment Oct 25, 2024

Dividend

Ex-dividend Jul 18, 2024

HK$0.4407

Semi-Annual

Record Jul 19, 2024 · Payment Aug 27, 2024

Dividend

Ex-dividend Jul 18, 2023

HK$0.6638

Annual

Record Jul 19, 2023 · Payment Aug 28, 2023

2607.HK peers

ETFs holding 2607.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 2607.HK

research.disclaimer